Pain Alchemy podcast

GLP-1s, Endo & PMOS: Hype vs Evidence

11/3/2026
0:00
20:35
Rewind 15 seconds
Fast Forward 15 seconds

Ozempic, Mounjaro, and the viral grey-market “Reta” are everywhere in endo forums, but what do they actually do for endometriosis, PMOS, and fertility?

In this episode, I cut through the hype with a clear-eyed breakdown of the science, the risks, and why some of the most exciting online claims are still running ahead of the evidence.

As a clinical naturopath living with endometriosis, PMOS, interstitial cystitis, and vulvodynia, I know why these drugs can feel so tempting when you’ve spent years searching for relief.

But this conversation isn’t about shame or fearmongering. It’s about giving you the facts so you can make safer choices, ask better questions, and avoid getting burned by forum advice or unregulated injections.

You’ll hear me explain:

  • What GLP-1s are and how semaglutide, tirzepatide, and retatrutide differ
  • Why the strongest human evidence so far is in PMOS, especially around insulin resistance, ovulation, testosterone, and cycle regularity
  • What researchers have found so far in endometriosis, including immune signaling, inflammation, fibrosis, and pelvic fluid studies
  • Why the online buzz around “Reta” is especially risky, from illegal supply chains to contamination, incorrect doses, and adverse reactions
  • What to ask your doctor before considering a GLP-1, including questions about pregnancy, contraception, medication timing, and red-flag side effects.


I also talk about why this conversation matters so much for people with endometriosis and PMOS: these conditions are often dismissed, appetite suppression can be risky for people with a history of restrictive eating, and quick fixes can distract from the deeper drivers of pain.

If you’ve seen these drugs recommended as a miracle solution, I offer a grounded, evidence-based reality check.

This episode is for anyone with endometriosis or PMOS, anyone considering a GLP-1, or anyone who wants to know what’s real before trusting the hype.

@bethleenaturopath
bethleenaturopath.com


Resourse:

  • Krasnyi et al. (2022). GLP-1 and other factors decreased in peritoneal fluid of women with endometriosis. Int J Mol Sci. doi.org/10.3390/ijms231810361
  • Hoteit et al. (2025). The dual impact of GLP-1 receptor agonists on metabolic and reproductive health in PCOS. Ther Adv Endocrinol Metab. doi.org/10.1177/20420188251383064
  • Sola-Leyva et al. (2025). The hidden impact of GLP-1 receptor agonists on endometrial receptivity and implantation. Acta Obstet Gynecol Scand. doi.org/10.1111/aogs.15010
  • Teede et al. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. Overview of the rename

Retatrutide and safety

More episodes from "Pain Alchemy"